Progressive Amyloid‐Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier
European Journal of Neurology · 2026-10 · 33 (10)
DOI: 10.1111/ene.70779 ↗At a glance
Fallbericht in European Journal of Neurology, published online on 2026-10-12. Written by Elisabeth Stögmann and 12 co-authors. Institution: Department of Neurology, Medical University of Vienna, Wien, Austria. Major MEDLINE topics: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Cited 1 times so far (Crossref); 7 references. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Demenz
Abstract (original language)
Background
Amyloid‐related imaging abnormalities (ARIA) are the most relevant adverse events associated with anti‐amyloid therapies in Alzheimer's disease.
Methods
We report a case of progressive ARIA after discontinuation of lecanemab in a patient with early‐onset Alzheimer's disease carrying the rare APOE ε2/ε4 genotype.
Results
After two infusions, mild ARIA‐edema (ARIA‐E) and ARIA‐hemorrhage (ARIA‐H) were detected on routine MRI, prompting treatment interruption. Despite partial radiologic regression, follow‐up MRI 8 weeks after discontinuation demonstrated marked progression with multifocal ARIA‐H displaying as superficial siderosis, while the patient remained clinically asymptomatic. Corticosteroid treatment was initiated and lecanemab permanently discontinued.
Conclusion
This case highlights that severe ARIA may progress beyond active treatment exposure and emphasizes the importance of continued MRI surveillance even after therapy cessation. Furthermore, the APOE ε2/ε4 genotype may represent a distinct risk factor for cerebral amyloid angiopathy‐related vascular fragility and hemorrhagic ARIA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Medical University of Vienna, Wien, Austria.
- Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Wien, Austria.
- Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Wien, Austria.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Wien, Austria.
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Wien, Austria.
ORCID profiles: Elisabeth Stögmann, Lukas Haider, Joel Leinkauf, Helena Untersteiner, Tandis Parvizi, Raphael Wurm, Gregor Kasprian, Thomas Berger, Ellen Gelpi, Evelyn Berger Sieczkowski
Cite
APA
Stögmann, E., Haider, L., Leinkauf, J., Nakuz, T., Untersteiner, H., Farr, C., Silvaieh, S., Parvizi, T., Wurm, R., Kasprian, G., Berger, T., Gelpi, E., & Sieczkowski, E. B. (2026). Progressive Amyloid‐Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier. European Journal of Neurology, 33(10). https://doi.org/10.1111/ene.70779
Vancouver
Stögmann E, Haider L, Leinkauf J, Nakuz T, Untersteiner H, Farr C, et al. Progressive Amyloid‐Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier. European Journal of Neurology. 2026;33(10). doi:10.1111/ene.70779
BibTeX
@article{Stgmann2026,
author = {Stögmann, Elisabeth and Haider, Lukas and Leinkauf, Joel and Nakuz, Thomas and Untersteiner, Helena and Farr, Clemens and Silvaieh, Sara and Parvizi, Tandis and Wurm, Raphael and Kasprian, Gregor and Berger, Thomas and Gelpi, Ellen and Sieczkowski, Evelyn Berger},
title = {Progressive Amyloid‐Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {10},
doi = {10.1111/ene.70779}
}
EUVIMED